These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30663547)

  • 41. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
    Herbrecht R; Rajagopalan S; Danna R; Papadopoulos G
    Curr Med Res Opin; 2010 Oct; 26(10):2457-64. PubMed ID: 20822354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer's safety database.
    O'Flynn R; Zhou YP; Waskin H; Leong R; Straus W
    Expert Opin Drug Saf; 2022 Aug; 21(8):1113-1120. PubMed ID: 35232318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
    Salavert M; Jarque I
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
    Groll AH; Walsh TJ
    Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
    Miceli MH; Kauffman CA
    Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
    Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis.
    Negroni R; Tobón A; Bustamante B; Shikanai-Yasuda MA; Patino H; Restrepo A
    Rev Inst Med Trop Sao Paulo; 2005; 47(6):339-46. PubMed ID: 16553324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
    Raad II; Graybill JR; Bustamante AB; Cornely OA; Gaona-Flores V; Afif C; Graham DR; Greenberg RN; Hadley S; Langston A; Negroni R; Perfect JR; Pitisuttithum P; Restrepo A; Schiller G; Pedicone L; Ullmann AJ
    Clin Infect Dis; 2006 Jun; 42(12):1726-34. PubMed ID: 16705579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant.
    Alexander BD; Perfect JR; Daly JS; Restrepo A; Tobón AM; Patino H; Hardalo CJ; Graybill JR
    Transplantation; 2008 Sep; 86(6):791-6. PubMed ID: 18813103
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activity of posaconazole in the treatment of central nervous system fungal infections.
    Pitisuttithum P; Negroni R; Graybill JR; Bustamante B; Pappas P; Chapman S; Hare RS; Hardalo CJ
    J Antimicrob Chemother; 2005 Oct; 56(4):745-55. PubMed ID: 16135526
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Posaconazole: another triazole antifungal of the new generation?].
    Müller C; Kohl V; Farowski F; Cornely OA
    Dtsch Med Wochenschr; 2008 Nov; 133(45):2345-8. PubMed ID: 18958831
    [No Abstract]   [Full Text] [Related]  

  • 52. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Posaconazole-Loaded Leukocytes as a Novel Treatment Strategy Targeting Invasive Pulmonary Aspergillosis.
    Baistrocchi SR; Lee MJ; Lehoux M; Ralph B; Snarr BD; Robitaille R; Sheppard DC
    J Infect Dis; 2017 Jun; 215(11):1734-1741. PubMed ID: 27799353
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity.
    Morris MI
    Am J Health Syst Pharm; 2009 Feb; 66(3):225-36. PubMed ID: 19179636
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers.
    Moton A; Krishna G; Wang Z
    J Clin Pharm Ther; 2009 Jun; 34(3):301-11. PubMed ID: 19646076
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
    Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
    N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Posaconazole: an oral triazole with an extended spectrum of activity.
    Rachwalski EJ; Wieczorkiewicz JT; Scheetz MH
    Ann Pharmacother; 2008 Oct; 42(10):1429-38. PubMed ID: 18713852
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Isavuconazole: Case Report and Pharmacokinetic Considerations.
    Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
    Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity.
    Hof H
    Mycoses; 2006; 49 Suppl 1():2-6. PubMed ID: 16961575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study.
    Shen Y; Huang XJ; Wang JX; Jin J; Hu JD; Yu K; Wu DP; Wang SJ; Yu L; Chen XQ; Liu T; Liang YM; Chen FP; Li Y; Shen ZX
    Int J Clin Pharmacol Ther; 2013 Sep; 51(9):738-45. PubMed ID: 23924680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.